Determining chromosomal arms 1p/19q co-deletion status in low graded glioma by cross correlation-periodogram pattern analysis

• Published in: Scientific reports 2021-12, Vol.11 (1), p.23866-23866, Article 23866
• Main Authors: Bhattacharya, Debanjali, Sinha, Neelam, Saini, Jitender
• Format: Article
• Language: English
• Subjects: 631/378; 631/67; 639/166; 692/308; 692/4028; 692/53; 692/617; 692/699; 692/700; Biopsy; Brain Neoplasms - diagnostic imaging; Brain Neoplasms - genetics; Brain Neoplasms - pathology; Brain tumors; Chromosome Deletion; Chromosomes, Human, Pair 1 - genetics; Chromosomes, Human, Pair 19 - genetics; Classification; Glioma; Glioma - diagnostic imaging; Glioma - genetics; Glioma - pathology; Heterogeneity; Humanities and Social Sciences; Humans; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; multidisciplinary; Patients; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-03078-1

Prediction of mutational status of different graded glioma is extremely crucial for its diagnosis and treatment planning. Currently FISH and the surgical biopsy techniques are the ‘gold standard’ in the field of diagnostics; the analyses of which helps to decide appropriate treatment regime. In this study we proposed a novel approach to analyze structural MRI image signature pattern for predicting 1p/19q co-deletion status non-invasively. A total of 159 patients with grade-II and grade-III glioma were included in the analysis. These patients earlier underwent biopsy; the report of which confirmed 57 cases with no 1p/19q co-deletion and 102 cases with 1p/19q co-deletion. Tumor tissue heterogeneity was investigated by variance of cross correlation (VoCC). Significant differences in the pattern of VoCC between two classes was quantified using Lomb-Scargle (LS) periodogram. Energy and the cut-off frequency of LS power spectral density were derived and utilized as the features for classification. RUSBoost classifier was used that yield highest classification accuracy of 84% for G-II and 87% for G-III glioma respectively in classifying 1p/19q co-deleted and 1p/19q non-deleted glioma. In clinical practice the proposed technique can be utilized as a non-invasive pre-confirmatory test of glioma mutation, before wet-lab validation.